"Maytansine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.
Descriptor ID |
D008453
|
MeSH Number(s) |
D02.540.505.495 D04.345.295.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Maytansine".
Below are MeSH descriptors whose meaning is more specific than "Maytansine".
This graph shows the total number of publications written about "Maytansine" by people in this website by year, and whether "Maytansine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 2 | 3 |
2014 | 1 | 2 | 3 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 3 | 0 | 3 |
2020 | 3 | 0 | 3 |
2021 | 1 | 1 | 2 |
2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Maytansine" by people in Profiles.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
-
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial. Lancet Oncol. 2022 04; 23(4):540-552.
-
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
-
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
-
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515.
-
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 12 15; 126(24):5303-5310.
-
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020 06 01; 38(16):1824-1835.
-
Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene. 2018 04; 37(17):2251-2269.
-
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 01; 19(1):115-126.
-
Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. J Oncol Pract. 2017 08; 13(8):555-556.